1. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
- Author
-
Carhart-Harris, RL, Bolstridge, M, Day, CMJ, Rucker, J, Watts, R, Erritzoe, DE, Kaelen, M, Giribaldi, B, Bloomfield, M, Pilling, S, Rickard, JA, Forbes, B, Feilding, A, Taylor, D, Curran, HV, and Nutt, DJ
- Subjects
Depression ,Brain Disorders ,Mental Health ,Clinical Trials and Supportive Activities ,Clinical Research ,Behavioral and Social Science ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Mental health ,Good Health and Well Being ,Adult ,Antidepressive Agents ,Combined Modality Therapy ,Depressive Disorder ,Treatment-Resistant ,Double-Blind Method ,Feasibility Studies ,Female ,Follow-Up Studies ,Hallucinogens ,Humans ,Male ,Middle Aged ,Psilocybin ,Psychosocial Support Systems ,Time Factors ,Treatment Outcome ,5-HT2AR ,Hallucinogen ,Mood ,Psychedelic ,Psychotherapy ,Serotonin ,Treatment-resistant depression ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Psychiatry - Abstract
RationaleRecent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy.ObjectivesHere, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression.MethodsTwenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting. Depressive symptoms were assessed from 1 week to 6 months post-treatment, with the self-rated QIDS-SR16 as the primary outcome measure.ResultsTreatment was generally well tolerated. Relative to baseline, marked reductions in depressive symptoms were observed for the first 5 weeks post-treatment (Cohen's d = 2.2 at week 1 and 2.3 at week 5, both p
- Published
- 2018